The World Health Organization has announced the members of its gene-editing committee, according to NPR.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
Business Insider reports on efforts to apply genetic engineering to cacao plants.
In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.
The team engineered an enhanced Acidaminococcus sp. Cas12a variant that has the ability to target many previously inaccessible protospacer adjacent motifs.
Sangamo Therapeutics has announced preliminary results from its gene-editing trial, the Associated Press reports.
The Financial Times looks into the use of gene editing within agriculture.
Technology Review reports that Stanford University is investigating what its faculty members knew about He Jiankui's effort to edit the genomes of human embryos.
In Nature this week: new CRISPR nuclease described, gut bacteria reference, and more.
The company said the financing will further support its strategy of translating its genome editing platforms into potential therapeutics and drug-discovery solutions.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.